A study to evaluate the hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy in patients with metastatic renal cell carcinoma.
Phase of Trial: Phase IV
Latest Information Update: 10 Dec 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Pharmacodynamics
- 10 Dec 2015 New trial record